C-suite shuffle: Amgen CFO Peacock resigns

Amgen ($AMGN) says CFO Jonathan Peacock is stepping down from that position today. The company gave the leaving "to pursue broader career opportunities" explanation. The company named Michael Kelly, an 11-year Amgen veteran, to hold the CFO position on an interim basis. The Los Angeles Times says that Peacock, who has been at the company since 2010, actually is going to hang around until May to help with the transition. It is an important time for Amgen, which is integrating Onyx Pharmaceuticals into its operations after its $10.4 billion buyout of Onyx last year. It picked up the company to get control of Kyprolis, the multiple myeloma drug that is forecast to have sales of $2 billion to $2.4 billion by 2019. Release | More

Suggested Articles

Researchers scoured the database where pharma companies disclose payments made to physicians and discovered a troubling trend.

Just a few months after playing a pivotal role in Sanofi’s Bioverativ buy, Alex Denner has set his sights on Ironwood.

Clovis' new approval will boost Rubraca in recurrent ovarian cancer, but because of its competitors' head start, the race will be tough.